



BACHEM

Bachem acquires American Peptide Company

Bubendorf/Basel, February 27, 2015 – Bachem (SIX: BANB), the leading peptide manufacturer, announced today the forthcoming acquisition of American Peptide Company, Inc. (APC), based in California, USA. The seller ILS, Inc. (Moriya, Japan), a wholly-owned subsidiary of Otsuka Chemical Co., Ltd. (Osaka, Japan), and the buyer, Bachem Americas, Inc. (Torrance, USA) have signed a contract to transfer all shares of APC. Both parties have agreed not to disclose the terms of the deal.

American Peptide Company, a direct competitor of Bachem, provides a wide range of services from small-scale catalog business and custom synthesis to large-scale manufacturing under cGMP. The company runs two sites at Sunnyvale and Vista, California, and has 86 employees.

Dr. Thomas Früh, CEO of the Bachem Group comments: *“The acquisition of APC is an important step in further enhancing the global leadership of Bachem in peptides. It strengthens our position in the USA, the world largest peptides market, and provides immediate access to additional large-scale production capacity for our world-wide growing project portfolio. Furthermore, we consolidate our position in the highly demanding Japanese market. The profile of both companies fit extremely well and I am sure that customers as well as employees of APC will benefit from and appreciate the combined strengths of both companies.”*

Mr. Takahiro Ogata, President of ILS Inc., continues: *“It is a great opportunity for APC to join the leader in the peptide field.”* and he adds: *“We are particularly enthusiastic to extend our partnership with Bachem. They are a highly reliable source of research grade peptides from catalog and custom synthesis as well as cGMP manufactured large scale peptides. Based on this collaboration, ILS can offer the largest selection of research grade peptides and APIs in Japan, and access a broad portfolio for its customers.”*

About Bachem

Bachem is a listed technology-based company focused on peptide chemistry. The company provides a full range of services to the pharma and biotech industries. It specializes in the development of innovative, efficient manufacturing processes and the reliable production of peptide-based active pharmaceutical ingredients. A comprehensive catalog of biochemicals and exclusive custom syntheses for research labs complete the service portfolio. Headquartered in Switzerland with subsidiaries in Europe and the US, the group has a global reach with more experience and know-how



BACHEM

than any other company in the industry. Towards its customers, Bachem shows total commitment to quality, innovation and partnership.

Bachem. Pioneering Partner for Peptides

About ILS

ILS, Initiative for Life Sciences, has been engaged in the business of pharmaceuticals and functional foods for more than 20 years in Japan. ILS holds marketing approval for peptidic pharmaceuticals and has broad experience in research, development and formulation of peptides.

About American Peptide Company

American Peptide Company, Inc. (APC) offers a comprehensive selection of pre-manufactured catalog peptides, a complete spectrum of non-GMP custom synthesis services from array screens to mg and kg quantities as well as large scale manufacturing of API peptides for clinical studies at its cGMP plant in Vista. APC is dedicated to deliver high quality peptides to pharmaceutical and biotech companies worldwide.

Contact:

For further questions, please visit our websites or contact the person below.

Bachem Holding AG
Stephan Schindler, CFO
Tel.: +41 61 935 2333
Fax: +41 61 935 2324
ir@bachem.com
www.bachem.com

ILS, Inc.
Takahiro Mizumoto, Operating Officer, Senior Manager of Sales dept.
Tel.: +81 297 45 6342
Fax. +81 297 45 6353
info@ils.co.jp
www.ils.co.jp